Ardent Health Partners: Cost Efficiencies Balance Utilization Headwinds, Justifying a Hold Rating

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Hold rating on Ardent Health Partners, Inc.. The associated price target is $12.00.

Craig Hettenbach has given his Hold rating due to a combination of factors tied to Ardent Health Partners, Inc.’s recent performance and outlook. The company’s latest quarter showed essentially flat revenue with some negative mix trends, as growth in inpatient surgeries was offset by weaker outpatient volumes and emergency room visits, and overall 2026 guidance came in slightly below market expectations on both revenue and EBITDA.

At the same time, Hettenbach sees balancing positives from Ardent’s cost-control and efficiency initiatives, including an expanded savings target from its IMPACT program and early benefits from technology and AI adoption that should improve operating leverage over time. However, these efforts are tempered by anticipated headwinds from the health insurance exchange subsidy expiration, which is expected to weigh on admissions and utilization, leading him to conclude that risk and reward are currently in rough equilibrium, supporting a Hold rather than a more decisive rating change.

In another report released yesterday, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $10.50 price target.